Our findings may help in identifying novel therapeutic targets to improve the quality of life of the elderly, as favoring normal values of the CD4/CD8 T-cell ratio might improve vaccine responses and reduce the risk of infection, such as that by the novel SARS-CoV-2 virus, as well as the risk of cardiovascular disease and cancer. This evidence concerns the gene CD8A and cancer.